Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124942702 | 12494270 | 2 | F | 201601 | 20160630 | 20160623 | 20160707 | EXP | PHHY2016AR085296 | NOVARTIS | 73.39 | YR | M | Y | 0.00000 | 20160707 | CN | COUNTRY NOT SPECIFIED | AR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124942702 | 12494270 | 1 | PS | DIOVAN | VALSARTAN | 1 | Unknown | 160 MG, QD | U | 20665 | 160 | MG | QD | ||||||
| 124942702 | 12494270 | 2 | SS | DIOVAN | VALSARTAN | 1 | Unknown | 320 MG, ONCE/SINGLE | U | 20665 | 320 | MG | 1X | ||||||
| 124942702 | 12494270 | 3 | SS | DIOVAN | VALSARTAN | 1 | Unknown | 160 MG, QD | U | 20665 | 160 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124942702 | 12494270 | 1 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124942702 | 12494270 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124942702 | 12494270 | Asthenia | |
| 124942702 | 12494270 | Fall | |
| 124942702 | 12494270 | General physical health deterioration | |
| 124942702 | 12494270 | Patella fracture |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |